ArticleHIV medicine2026
Calibration and discrimination ability of the Dat'AIDS score in people living with HIV aged 70 years and older from the Dat'AIDS cohort.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe Dat'AIDS score was developed to predict 5-year mortality risk in people living with HIV aged 60 and older. However, its validity in people living with HIV aged 70 years and older needed confirmation.
methodsThis was a multicentre prospective cohort study in the Dat'AIDS French cohort. We calculated the Dat'AIDS score and Veterans Aging Cohort Study (VACS) indices 1.0 and 2.0 in people living with HIV aged 70 or older, at their first medical visit between 01/06/2014 and 31/12/2017. Participants were followed until 31 December 2019 (before the COVID-19 era). Discrimination and calibration of the Dat'AIDS score were assessed using Harrell's C-statistic and comparisons of predicted versus observed survival probabilities. The comparison of the discriminative capacity of the Dat'AIDS score with the VACS indices was performed.
resultsA total of 1330 participants (75.5% male, median age: 73.7 years, median time since HIV diagnosis: 21.7 years, median time under combination antiretroviral therapy (cART): 19.9 years, median CD4 cell count: 553 cells/μL, HIV-1 RNA ≤50 copies/mL: 88.7%) were included. Overall, 221 (16.6%) deaths were recorded during 5598 patient-years of follow-up. The Dat'AIDS score showed good discrimination (C-statistic: 0.72; 95% confidence interval [CI; 0.68-0.75]). Calibration was good except for the moderate-risk group (5% difference). The Dat'AIDS score showed better discrimination than VACS 1.0 and 2.0 with albumin, aspartate aminotransferase (AST) and alanine transaminase (ALT) normal value imputation (C-statistic: 0.72 vs. 0.69 for both) and was similar to VACS 2.0 without imputation (0.72 vs. 0.71), that could be calculated in 99.1%, 98.6% and 34.0%, respectively.
conclusionsThe Dat'AIDS score showed good discrimination and calibration in people living with HIV aged 70 years and older, providing an easy and valuable tool for clinical decision-making and research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.